ANO7 and prostate carcinoma: ANO7 exhibits restricted tissue expression and is highly expressed in normal and cancerous prostate where it localizes to apical and lateral membrane regions and may regulate cell aggregation; accordingly ANO7 represents a target for prostate cancer immunotherapy [35]–[37].